MAPLIGHT THERAPEUTICS APPOINTS TIM GARNETT, M.D. TO BOARD OF DIRECTORS
SAN FRANCISCO, July 24, 2023 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, today announced the appointment of Tim Garnett, M.D. to its Board of Directors. Dr. Garnett is a pharmaceutical executive with decades of experience in drug development and strategic portfolio management.
- SAN FRANCISCO, July 24, 2023 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, today announced the appointment of Tim Garnett, M.D.
- Dr Garnett has served on multiple boards and is currently Board Chair of Ophirex, a Board Member of Carmot Therapeutics and a member of the Advisory Panel of Cambridge Innovation Capital.
- "I am proud to join MapLight's Board of Directors as the company moves multiple drug candidates through development and on to registrational trials," said Tim Garnett, MD.
- "MapLight has a promising pipeline of novel assets and a talented leadership team of distinguished neuroscience veterans unique within biopharma.